Transition of CFO at Viatris: Paul Campbell Steps in as Interim Leader

Viatris Announces CFO Transition

Viatris Inc., the global healthcare company recognized for its commitment to empowering healthier lives, has declared a significant change in its executive leadership team. The Chief Financial Officer, Theodora "Doretta" Mistras, has decided to step down for a new professional opportunity. Her departure is set for May 22, 2026, allowing for a transition period in which she will assist the company in achieving a smooth handover.

To fill the void left by Mistras, Paul Campbell, who is currently serving as the Chief Accounting Officer and Corporate Controller of Viatris, has been appointed interim Chief Financial Officer, effective May 8, 2026. The company is in the process of finding a permanent successor to take over from Mistras while Campbell utilizes his vast experience to ensure operational continuity during this transitional phase.

Scott A. Smith, CEO of Viatris, expressed gratitude for Mistras's contributions to the company. He stated, "We thank Doretta for her significant contributions, which have helped prepare the Company to enter a period of sustainable future growth." Mistras has been instrumental in maintaining the financial integrity and strategic direction of Viatris since the company was formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. Her leadership has been crucial in guiding Viatris toward sustainable growth and innovation in addressing global healthcare needs.

Paul Campbell brings over two decades of experience in finance and corporate leadership, having joined the legacy company Mylan in 2002. Over the years, he has held various leadership positions that have sharpened his expertise in accounting and financial operations. In his current role, he oversees the global accounting and finance operations, where he has been responsible for enhancing financial processes and supporting strategic initiatives. His background not only includes extensive experience within the healthcare sector but also a solid foundation in auditing from his previous tenure at Deloitte Touche.

The leadership transition occurs at a significant moment for Viatris, which is preparing to disclose its financial results for the first quarter of 2026 on May 7, 2026. Following the release, the company will conduct a conference call at 8:30 a.m. ET to discuss the outcomes, emphasizing its commitment to transparency and investor engagement.

Viatris's mission is to leverage its expertise to meet the healthcare needs of patients globally. Whether through the development of new medications, ensuring resilient supplies of necessary therapies, or pursuing innovative solutions, Viatris is dedicated to making a positive impact in healthcare. The company portfolio, which includes generics, established brands, and innovative therapies, showcases their commitment to addressing significant unmet medical needs.

In conclusion, while the departure of a key executive like Doretta Mistras marks a notable transition for Viatris, the appointment of Paul Campbell as interim CFO promises stability and continuity. As the company positions itself for future growth, both leadership and innovation will remain at the forefront of its operations. The ongoing developments will be closely watched by stakeholders and industry analysts alike, as Viatris continues to navigate the complexities of the global healthcare landscape.

For more information about Viatris and its ongoing impact on health and well-being, visit Viatris.com.